Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/17/2014 07/18/2014 07/21/2014 07/22/2014 07/23/2014 Date
27.54(c) 28.74(c) 28.65(c) 29.93(c) 31.39(c) Last
1 774 258 1 557 220 1 080 123 1 441 921 1 979 425 Volume
-4.34% +4.36% -0.31% +4.47% +4.88% Change
More quotes
Company
Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer. The company operates in two segments: Drug Discovery & Development and Regulus. 
Surperformance© rating of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More about the company
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 170 M
EBIT 2014 -68,7 M
Net income 2014 -84,6 M
Finance 2014 268 M
Yield 2014 -
Sales 2015 160 M
EBIT 2015 -97,0 M
Net income 2015 -126 M
Finance 2015 218 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 18,3x
EV / Sales 2015 19,7x
Capitalization 3 369 M
More Financials
Latest news on ISIS PHARMACEUTICALS, INC.
1h ago ISIS PHARMACEUTICALS : Initiates Phase 2 Study of ISIS-APOa Rx in Patients with ..
6d ago ISIS PHARMACEUTICALS : Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients wit..
07/16 ISIS PHARMACEUTICALS : Earns $1 Million from GSK for Advancing ISIS-TTR Rx
07/15 ISIS PHARMACEUTICALS : Excaliard Pharmaceuticals Assigned Patent
07/09 ISIS PHARMACEUTICALS : New Cancer Gene Therapy Study Findings Reported from Isis..
07/08 ISIS PHARMACEUTICALS : Assigned Patent
07/02 GLAXOSMITHKLINE : Isis Pharma Earns USD1 Million From Glaxo For Advancing Hepati..
07/02 ISIS PHARMACEUTICALS : Earns $1 Million From GSK for Advancing Hepatitis B Virus..
07/02 ISIS PHARMACEUTICALS : to Speak at Pharmica Consulting's West Coast SharePoint C..
06/26 ISIS PHARMACEUTICALS : Earns $10 Million Milestone Payment from Biogen Idec
06/24 ISIS PHARMACEUTICALS : Earns $1 Million From GSK for Advancing ISIS-TTR Rx
06/18 ISIS PHARMACEUTICALS : Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
ISIS Pharmaceuticals, Inc. : Income Statement Evolution
More Financials
EPS Revisions
ISIS Pharmaceuticals, Inc. : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF